Tangui Barré, Marc Bourlière, Lucia Parlati, Clémence Ramier, Fabienne Marcellin, Camelia Protopopescu, Vincent Di Beo, Carole Cagnot, Celine Dorival, Jérôme Nicol, Fabien Zoulim, Fabrice Carrat, Patrizia Carrieri
INTRODUCTION: The risk of mortality in people with a history of injection drug use (PHID) is high, as is the prevalence of hepatitis C virus (HCV) infection. Although direct-acting antivirals (DAA) are effective in this population in terms of sustained virological response, it is not known whether PHID benefit as much as people with no history of injection drug use from DAA-related HCV cure in terms of reduced all-cause mortality. METHODS: Using Cox proportional hazards models based on the ANRS CO22 Hepather cohort data (n = 9735), we identified factors associated with all-cause mortality among HCV-infected people...
December 22, 2023: Drug and Alcohol Review